NEW YORK--(BUSINESS WIRE)--
Levi & Korsinsky announces it has commenced an investigation of Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) concerning possible violations of federal securities laws.
On January 19, 2017, Catabasis issued positive statements about its Phase 1 trials for edasalonexent (CAT-1004), stating that the results supported the continued development of the treatment for the treatment of Duchenne Muscular Dystrophy. Then on January 31, 2017, Catabasis announced disappointing results for its mid-stage clinical trial, noting that the study failed to meet its primary endpoint. Following this news, shares of Catabassis fell from a close of $4.04 per share on January 31, 2017, to $1.18 per share the following day. To obtain additional information, go to:
http://zlk.9nl.com/catabasis-catb
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170202005905/en/
